How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Spinal Muscular Atrophy Market
- By SMA Type: 5q Spinal Muscular Atrophy, Non-5q Spinal Muscular Atrophy, Adult-Onset SMA, Infantile-Onset SMA
- By Treatment Type: Gene Therapy, Antisense Oligonucleotides (ASO), Small Molecule Therapy, Supportive Care, Physical Therapy
- By Patient Age Group: Pediatric Patients, Adult Patients, Neonatal Patients
- By Disease Severity: Severe SMA, Moderate SMA, Mild SMA
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Home Care Settings, Retail Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 5q Spinal Muscular Atrophy leads By SMA Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Spinal Muscular Atrophy Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
By SMA Type 4
By Treatment Type 5
By Patient Age Group 3
By Disease Severity 3
By Distribution Channel 4
Companies profiled
Roche (Genentech)
Novartis
Biogen
Pfizer
AveXis (a Novartis company)
Ionis Pharmaceuticals
Sarepta Therapeutics
PTC Therapeutics
Bristol-Myers Squibb
Sanofi
Amicus Therapeutics
Ultragenyx Pharmaceutical
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche (Genentech)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Biogen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AveXis (a Novartis company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ionis Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Sarepta Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →PTC Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Amicus Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Ultragenyx Pharmaceutical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,227M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 5q Spinal Muscular Atrophy45.7
- Non-5q Spinal Muscular Atrophy15.3
- Adult-Onset SMA17.1
- Infantile-Onset SMA21.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,307M → $2,684M · 9.4%
Europe$910.6M → $1,821M · 9.1%
Asia Pacific$831.4M → $1,739M · 9.7%
Latin America$514.7M → $1,125M · 10.3%
Middle East and Africa$395.9M → $827.7M · 9.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.522026
9.532027
9.552028
9.562029
9.582030
9.602031
9.592032
9.602033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche (Genentech)21.6
- Novartis23.2
- Biogen7.6
- Pfizer6.2
- AveXis (a Novartis company)5.1
- Ionis Pharmaceuticals8.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →By SMA Type15.6%
By Treatment Type20.0%
By Patient Age Group20.9%
By Disease Severity28.9%
By Distribution Channel14.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe22.2
- Asia Pacific21.2
- Latin America13.7
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche (Genentech) | 99 | 77 | 86 | 75 | 79 | 83 | 83 |
| Novartis | 71 | 76 | 89 | 71 | 71 | 76 | 76 |
| Biogen | 65 | 70 | 73 | 87 | 70 | 69 | 72 |
| Pfizer | 61 | 78 | 68 | 81 | 59 | 59 | 68 |
| AveXis (a Novartis company) | 65 | 55 | 59 | 68 | 52 | 66 | 61 |
| Ionis Pharmaceuticals | 58 | 62 | 67 | 62 | 71 | 49 | 62 |
| Sarepta Therapeutics | 51 | 56 | 43 | 64 | 48 | 43 | 51 |
| PTC Therapeutics | 44 | 48 | 58 | 58 | 45 | 55 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche (Genentech)
- Novartis
- Biogen
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche (Genentech) | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Novartis | − | ◐ | ✓ | ✓ | ✓ | ◐ |
| Biogen | ✓ | ◐ | ◐ | ✓ | ✓ | − |
| Pfizer | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| AveXis (a Novartis company) | ◐ | ◐ | ◐ | − | − | ✓ |
| Ionis Pharmaceuticals | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Sarepta Therapeutics | − | ◐ | ◐ | ✓ | − | ◐ |
| PTC Therapeutics | ◐ | ◐ | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche (Genentech)83
2Novartis76
3Biogen72
4Pfizer68
5Ionis Pharmaceuticals62
6AveXis (a Novartis company)61
7Sarepta Therapeutics51
8PTC Therapeutics51
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche (Genentech)
Challenger3
Strong scale, closing on the leaders.
NovartisBiogenPfizer
Contender2
Focused players with pockets of strength.
AveXis (a Novartis company)Ionis Pharmaceuticals
Niche2
Specialists in a single segment or region.
Sarepta TherapeuticsPTC Therapeutics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By SMA Type in North America, then scale across Spinal Muscular Atrophy Market — a $109M beachhead inside a $1.81B market.
Beachhead (SOM)$109Mobtainable near-term
Serviceable (SAM)$739Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
5q Spinal Muscular Atrophy
Best fit — highest urgency & budget in By SMA Type.
Economic buyer77 fit
Non-5q Spinal Muscular Atrophy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Adult-Onset SMA
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By SMA Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel28%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For By SMA Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Spinal Muscular Atrophy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation12%
Closed-won5%
$20.1KCAC
$110KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Spinal Muscular Atrophy Market is a durable-growth opportunity — $5.58B by 2033, compounding at 7.1%.
TAM · 2025$3.22Btoday
TAM · 2033$5.58Bforecast
CAGR7.1%2027–2033
Cumulative$38.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.58BTotal addressable market
SAM$1.95BServiceable available market
SOM$362MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.1% CAGR
Demand compounds through 2033, outpacing GDP across By SMA Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By SMA Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.58BLarge & growingTAM by 2033 at 7.1% CAGR
$1.95BServiceable nowreachable with today’s model
$362MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.36BBear4.6% CAGR
$5.58BBase7.1% CAGR
$7.15BBull9.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Spinal Muscular Atrophy Market — a $6.97B market by 2033. Plan: grow share from 7.2% to 12.1%.
Market size · 2033$6.97Btotal addressable
Market CAGR5.7%2027–2033
Target share12.1%from 7.2% today
Revenue ambition$844Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 12.1% | On track |
| Revenue | $523M | $844M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 28.8% | 44.4% | On track |
| Customer retention | 88.5% | 96.2% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By SMA Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Treatment Type capability
A defensible second engine — invest in By Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By SMA Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $90M capacity & capability investment
- Greenlight bolt-on M&A in By Treatment Type
- Authorise North America expansion plan
- Fund R&D program for By SMA Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Spinal Muscular Atrophy Market conversation — a $1.57B market you can size, segment and defend in minutes.
Market size · 2033$1.57Btotal opportunity
Growth5.5%CAGR to 2033
Addressable buyers1,305+accounts in scope
Typical ROI6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By SMA Type
Goal Grow share in By SMA Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6×return on cost, year one
< 2 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Roche (Genentech)NovartisBiogenPfizerAveXis (a Novartis company)Ionis PharmaceuticalsSarepta TherapeuticsPTC Therapeutics+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Spinal Muscular Atrophy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Spinal Muscular Atrophy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Renal Artery Stent Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportSurgical Imaging Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportStereotactic Surgery Devices Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportSerum Separating Tubes Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportElectric Dermatome Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThermoplastic Splints Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMedical Sterilizing Machines Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportHandheld DNA Readers Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportVitamin D2 Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDrug Screening Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportOphthalmic Surgical Technologies Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportIndustrial Dental 3D Printer Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.